Fig. 2
LINC01518 knockdown promotes apoptosis and reduces cell proliferation, migration, and invasion in HNSCC cells. (A) SCC-25 cells were transfected with ASO-NS or ASO-1/ASO-2, and cell viability was measured at indicated times using WST-1. (B) FaDu cells were transfected with ASO-NS or ASO-1/ASO-2, and cell viability was measured at indicated times using WST-1. (C) LINC01518 knockdown reduces the colony formation ability of HNSCC cells. (D) LINC01518 knockdown induces apoptosis in HNSCC cells, as indicated by the Caspase 3/7 activity assay. (E) Matrigel invasion assay shows that LINC01518 knockdown reduces HNSCC cell invasion. (F) Wound healing assay demonstrates reduced SCC-25 cell migration upon LINC01518 knockdown. (G) Wound healing assay demonstrates reduced FaDu cell migration upon LINC01518 knockdown. (H) LINC01518 knockdown with ASO-1 (25 nM) in combination with cisplatin treatment (10 µM for SCC-25 and 5 µM for FaDu) shows enhanced reduction in HNSCC percentage cell viability and increased sensitivity to cisplatin, as analyzed using WST-1 assay. (I) LINC01518 knockdown (25 nM of ASO-1) combined with cisplatin treatment (10 µM for SCC-25 and 5 µM for FaDu) shows enhanced caspase 3/7 activity compared to cisplatin alone. Data information: (For A-I) Error bars represent the mean ± SEM from three independent experiments. (For A–G) *Significant change compared to ASO-NS (p < 0.05). (For H, I) *Significant change compared to Control+ASO-NS treated cells (p < 0.05). #Significant change compared to Control+ASO-1 treated cells (p < 0.05). Statistical comparisons were made using the Student’s t-test.
